Taysha Gene Therapies, Inc. TSHA Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s return on equity?
- Taysha Gene Therapies, Inc. (TSHA) reported return on equity of -97.3% in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s return on equity changed year-over-year?
- Taysha Gene Therapies, Inc.'s return on equity increased by 38.9% year-over-year, from -159.3% to -97.3%.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s return on equity?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s return on equity has grown at a -12.1% compound annual growth rate (CAGR), from -100.7% to -68.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.